標題：匹那妥珠單抗，Pinatuzumab，CAS:1313706-14-7， AntibodySystem Laboratories
貨號：DHD38506
別名：ACD22-VCMMAE, DCDT2980S, FCU2803, RG-7593, RO5541072-000
簡介：
Pinatuzumab 是一種 CD22 單克隆抗體。Pinatuzumab 靶向細胞表面抗原 CD22。Pinatuzumab 可用于合成抗體藥物偶聯(lián)物 (ADC)，以研究包括非霍奇金淋巴瘤 (NHL) 在內(nèi)的多種疾病。
形態(tài)：Liquid
保存：0.01M PBS, pH 7.4.
濃度：1 mg/ml
純度：>95%
克隆性：Monoclonal
亞型：IgG1-kappa
應(yīng)用：Research Grade Biosimilar
靶點：ACD22-VCMMAE
產(chǎn)地：France
標記物：Unconjugate
品牌：AntibodySystem
抗原來源：Mammalian cells
適應(yīng)物種：Human
標識物：Unconjugate
保存條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -329°C long term.
參考文獻：
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). PMID: 30935953
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. PMID: 25708834
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. PMID: 27601593
Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma. PMID: 26194424
An Anti-CD22-seco-CBI-Dimer Antibody-Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models. PMID: 33273056
A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. PMID: 25840969
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). PMID: 25768997
Emerging antibody-drug conjugates for treating lymphoid malignancies. PMID: 28792782
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. PMID: 23598530
